Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback